A new treatment algorithm for posttraumatic stress disorder

Psychiatric Annals

Volumn 35, Issue 11, 2005, Pages 887-898

  Davidson, Jonathan ^{a,m,n,o,p,q,r,s,t,u}   Bernik, Marcio ^b   Connor, Kathryn M ^a,n,o   Friedman, Matthew J ^c,d   Jobson, Kenneth O ^e   Kim, Yoshiharu ^f   Lecrubier, Yves ^g,n,o,p,v,w   Ma, Hong ^h   Njenga, Frank ^i,j   Stein, Dan J ^k,n,o,p,q   Zohar, Joseph ^l,n  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NATIONAL CENTER FOR PTSD   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^g French National Institute of Health and Mental Research   (France)

^h CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

ⁱ Kenya Psychiatric Association   (Kenya)

^j African Association of Psychiatrists and Allied Professions   (Kenya)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

^l TEL AVIV UNIVERSITY   (Israel)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ PFIZER INC   (United States)

^o Solvay ^*  (United States)

^p GLAXOSMITHKLINE   (United States)

^q ASTRAZENECA   (United Kingdom)

^r BRISTOL MYERS SQUIBB   (United States)

^s UCB   (United States)

^t BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^u Sanofi Synthelabo Inc   (United Kingdom)

^v SANOFI   (France)

^w Centre d'Immunologie Pierre Fabre   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27844561428     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048-1060.
2. Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 1991;48(3):216-222.
3. Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry. 2000;61(Suppl 5):4-12; discussion 13-14.
4. Breslau N, Kessler RC, Chilcoat HD, et al. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch Gen Psychiatry. 1998;55(7):626-632.
5. The expert consensus guideline series. Treatment of Posttraumatic Stress Disorder. The Expert Consensus Panels for PTSD. J Clin Psychiatry. 1999;60(Suppl 16):3-76.
6. Foa EB, Keane T, Friedman M. Effective treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies. New York, NY: The Guilford Press; 2000.
7. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2000;61(Suppl 5):60-66.
8. Ursano RJ, Bell C, Eth S, et al.; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004;161(11 Suppl):3-31.
9. VA/DoD Clinical Practice Guideline for the Management of Post Traumatic Stress Disorders. Washington, DC: Department of Veterans Affairs/Department of Defense Clinical Practice Guideline Working Group. December 2003. Office of Quality and Performance publication 10Q-CPG/PTSD-04. Available at: http://www. oqp.med.va.gov/cpg/PTSD/PTSD_GOL.htm. Accessed September 30, 2005.
10. Post-traumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care. London, England; Gaskell; 2005. National Institute of Clinical Excellence Clinical Guideline 26. Available at: http://www.nice.org.uk/pdf/ CG026fullguideline.pdf. Accessed September 30, 2005.
11. Rothbaum BO, Foa EB, Davidson JRT, et al. Augmentation of sertraline with prolonged exposure in PTSD. Poster presented at: 159th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
12. Connor KM, Butterfield MI. Posttraumatic stress disorder. Focus: The Journal of Lifelong Learning in Psychiatry. 2003;1(3):247-262.
13. Amaya-Jackson L, Davidson JRT, Hughes DC, et al. Functional impairment and utilization of services associated with posttraumatic stress in the community. J Traumatic Stress. 1999;12(4):709-723.
14. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60(7):427-435.
15. Connor KM, Davidson JRT. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82.
16. Davidson JRT, Hughes D, Blazer DG, George LK. Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med. 1991;21(3):713-721.
17. Boscarino JA. Diseases among men 20 years after exposure to severe stress: implications for clinical research and medical care. Psychosom Med. 1997;59(6):605-614.
18. Schnurr PP, Green BL. Understanding relationships among trauma, post-traumatic stress disorder, and health outcomes. Adv Mind Body Med. 2004;20(1):18-29.
19. Davidson JRT. Recognition and treatment of posttraumatic stress disorder. JAMA. 2001;286(5):584-588.
20. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498- 1504.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
22. The International Statistical Classification of Diseases and Related Health Problems. 10th ed. Geneva, Switzerland: World Health Organization; 1992.
23. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283(14):1837-1844.
24. Davidson JRT, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58(5):485-492.
25. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158(12):1982-1988.
26. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(11):860-868.
27. Stein DJ, Davidson JRT, Seedat S, Beebe K. Paroxetine in the treatment of posttraumatic stress disorder: pooled analysis of placebo-controlled studies. Exp Opin Pharmacother. 2003;4(10):1829-1838.
28. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in posttraumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999 Jul; 175:17-22.
29. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63(3):199-206.
30. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994;55(12):517-522.
31. Seedat S, Lockhat R, Kaminer D, et al. An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol. 2001;16(1):21-25.
32. Seedat S, Stein DJ, Emsley RA. Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol. 2000;3(2):135-140.
33. Davidson JR, Weisler RH, Malik M, Tupler LA. Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol. 1998;18(1):93-95.
34. Escalona R, Canive JM, Calais LA, Davidson JR. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002;15(1):29-33.
35. Davidson JRT, Landerman LR, Farfel GM, Clary CM. Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med. 2002;32(4):661-670.
36. Davidson JRT, Landerman LR, Clary CM. Improvement of anger at week one predicts the effects of sertraline and placebo in PTSD. J Psychiatr Res. 2004;38(5):497-502.
37. Davidson JRT, Lipschitz A, Musgnung J. Treatment of PTSD with venlafaxine XR, sertraline, or placebo: a double-blind comparison. Int J Neuropsychopharmacol. 2004;7(1):P02.228.
38. Davidson JRT, Baldwin D, Stein D, et al. Venlafaxine-XR in the treatment of posttraumatic stress disorder: a 6-month placebo-controlled study. Neuropsychopharmacol. 2004;29(Suppl):S97.
39. Connor KM, Davidson JRT, Weisler RH, Ahearn E. A pilot study of mirtazapine in posttraumatic stress disorder. Int Clin Psychopharmacol. 1999;14(1):29-31.
40. Davidson JRT, Weisler RH, Butterfield MI, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003;53(2):188-191.
41. Davis LL, Nevels S, Nevels C, et al. Well-butrin for the treatment of posttraumatic stress disorder. Presented at: 39th Annual Meeting of the New Clinical Drug Evaluation Unit Program; June 1-4, 1999; Boca Raton, FL.
42. Davidson JRT, Kudler HS, Smith RD, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990;47(3):259-266.
43. Kosten TR, Frank J, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179(6):366-370.
44. Baker DG, Diamond BI, Gillette G, et al. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl). 1995;122(4):386-389.
45. Katz RJ, Lott MH, Arbus P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety. 1994-1995; 1(4):169-174.
46. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry. 1998;59(Suppl 15):35-41.
47. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 18):4-11.
48. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(Suppl 18):12-17.
49. Thase ME. Psychotherapy of refractory depressions. Depress Anxiety. 1997;5(4):190-201.
50. McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand. 2005;111(5):331-340.
51. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:218-222. US Department of Health, Education and Welfare publication (ADM) 76-388.
52. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(12):1974-1981.
53. Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002 Oct; 181:315-320.
54. Davidson JRT, Connor KM, Hertzberg MA, et al. Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol. 2005;25(2):166-169.
55. Davis LL, Jewell ME, Ambrose S, et al. A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin Psychopharmacol. 2004;24(3):291-297.
56. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990;51(6):236-238.
57. Connor KM, Davidson JRT, Weisler RH, Zhang W, Abraham KC. Tiagabine for posttraumatic stress disoarder. Presented at: 17th European College of Neuropsychopharmacology Congress; October 9-13, 2004; Stockholm, Sweden.
58. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226-1229.
59. Cohen H, Kaplan Z, Kotler M, et al. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2004;161(3):515-524.
60. Meltzer-Brody S, Connor KM, Churchill E, Davidson JR. Symptom-specific effects of fluoxetine in post-traumatic stress disorder. Int Clin Psychopharmacol. 2000;15(4):227-231.
61. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371-373.
62. Raskind MA, Thompson C, Petrie EC, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry. 2002;63(7):565-568.
63. Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for post-traumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacology. 1996;16(4):294-298.
64. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003;64(12):1421-1425.
65. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159(10):1777-1779.
66. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003;23(1):15-20.
67. Dieperink ME, Drogemuller L. Zolpidem for insomnia related to PTSD. Psychiatr Serv. 1999;50(3):421.
68. Mellman TA, Bustamante V, David D, Fins AI. Hypnotic medication in the aftermath of trauma. J Clin Psychiatry. 2002;63(12):1183-1184.
69. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996;57(9):390-394.
70. Krakow B, Hollifield M, Johnston L, et al. Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: a randomized controlled trial. JAMA. 2001;286(5):537-545.
71. Krakow B, Melendrez D, Pedersen B, et al. Complex insomnia: insomnia and sleep-disordered breathing in a consecutive series of crime victims with nightmares and PTSD. Biol Psychiatry. 2001;49(11):948-953.
72. Hamner MB, Frueh BC, Ulmer HG, Arana GW. Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry. 1999;45(7):846-852.
73. Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacology. 2003;23(2):193-196.
74. Hamner MB, Faldowski RA, Ulmer HG, et al. Adjunctive risperidone treatment in posttraumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003;18(1):1-8.
75. Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004; 65(12):1601-1606.
76. Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001;16(4):197-203.
77. Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with post-traumatic stress disorder. Psychiatr Serv. 2003;54(12):1618-1621.
78. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272.
79. Fesler FA. Valproate in combat-related post-traumatic stress disorder. J Clin Psychiatry. 1991;52(9):351-364.
80. Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999;12(2):395-401.
81. Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in posttraumatic stress disorder. Psychosomatics. 1986;27(12):849-854.
82. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004;4(1):24.
83. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63(1):15-20.
84. Londborg PD, Hegel MT, Goldstein S, et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001;62(5):325-331.
85. Davidson JRT. Surviving disaster: what comes after the trauma? Br J Psychiatry. 2002 Nov;181:366-368.
86. Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. J Consult Clin Psychol. 2000;68(5):748-766.